Table 2.
Interrupted time series regression analysis of change in the utilisation of LDTB patches in England
| BuTrans | Butec | Non-branded generic buprenorphine | Reletrans | Panitaz | Sevodyne | Bupramyl | Busiete | |
| β1 (February 2015–January 2016) | 62 430 (0.001) | |||||||
| β2 (February 2016) | 493 835 (0.067) | |||||||
| β3 (February 2016–August 2016) | −390 998 (0.000) | 406 565 (0.001) | ||||||
| β4 (September 2016) | −2 714 732 (0.000) | −1 338 836 (0.001) | ||||||
| β5 (September 2016–January 2018) | −285 157 (0.000) | 136 516 (0.028) | −167 411 (0.001) | 21 856 (0.001) | 1588 (0.001) | 17 217 (0.001) | 51.7 (0.453) | 42 (0.482) |
Savings from the introduction of Butec and other generic LDTB patches.
LDTB, low-dose buprenorphine.